AJ Wealth Strategies’s C4 Therapeutics CCCC Stock Holding History

AJ Wealth Strategies’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,007	Closed	-$75K	–	308
2022 Q2	$75K	Hold	10,007	–	–	﹤0.01%	295
2022 Q1	$243K	Hold	10,007	–	–	0.01%	278
2021 Q4	$322K	Hold	10,007	–	–	0.02%	241
2021 Q3	$447K	Hold	10,007	–	–	0.02%	200
2021 Q2	$379K	Buy	+10,007	New	+$358K	0.02%	206

Other funds holding CCCC

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

AJ Wealth Strategies's CCCC Position: Q3 2022 in Review

AJ Wealth Strategies sold out of C4 Therapeutics (CCCC) in Q3 2022, closing a stake of 10,007 shares — an estimated $75K sold.

AJ Wealth Strategies first reported a position in CCCC in Q2 2021 and held it in 5 quarters. The position peaked at $447K in Q3 2021. 114 funds tracked by Wall St. Rank hold CCCC as of Q3 2022.

AJ Wealth Strategies reported no remaining C4 Therapeutics position as of Q3 2022 after selling out during the quarter.
AJ Wealth Strategies sold 10,007 C4 Therapeutics shares in Q3 2022, an estimated $75K.
AJ Wealth Strategies first reported a position in C4 Therapeutics in Q2 2021 and held it in 5 quarters.
AJ Wealth Strategies's C4 Therapeutics position peaked at $447K in Q3 2021.
114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2022.

Based on AJ Wealth Strategies's 13F filing for Q3 2022, filed 27 Oct 2022.